Stay updated with breaking news from Barry Quart. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Heron Therapeutics, Inc. (NASDAQ:NASDAQ:HRTX) Q1 2022 Results Conference Call May 09, 2022 04:30 PM ET Company Participants David Szekeres - EVP and COO Barry Quart - Chairman and CEO John...
- ZYNRELEF® unit demand increased 68% in the first quarter compared to the prior quarter - - Centers for Medicare and Medicaid Services approved a 3-year...
/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing...
/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing...
Heron Therapeutics Announces Approval of ZYNRELEF® by Health Canada for the Management of Postoperative Pain - read this article along with other careers information, tips and advice on BioSpace